SPC97 Antibody

What is SPC97 and what cellular functions does it perform?

SPC97 is an essential spindle pole body (SPB) component with a calculated molecular mass of 97 kDa that interacts with γ-tubulin (Tub4p in yeast) and another SPB component, Spc98p. SPC97 encodes a protein of 823 amino acids that shows no significant homology to Spc98p or other proteins in the database . This protein is crucial for proper microtubule organization by the yeast microtubule organizing center.

Functionally, SPC97 is associated with both the inner and outer plaques of the SPB, the structures that organize nuclear and cytoplasmic microtubules, respectively. It forms complexes with Tub4p and Spc98p that are essential for multiple aspects of SPB function, including SPB duplication, SPB separation, and mitotic spindle formation . Mutation studies have demonstrated that temperature-sensitive spc97 mutants exhibit multiple spindle defects, underscoring its essential role in microtubule organization and cell division.

How is SPC97 antibody typically used in basic research protocols?

SPC97 antibodies are valuable tools for investigating SPB structure and function through several standard techniques:

• Immunofluorescence microscopy: SPC97 antibodies can be used to visualize SPB localization patterns. In normal cells, SPC97 appears as one or two distinct dots near the nuclear periphery, a staining pattern typical for SPB components . This technique allows researchers to track SPB duplication and separation during the cell cycle.

• Co-immunoprecipitation: Anti-SPC97 antibodies can precipitate SPC97 and its associated proteins, allowing researchers to identify protein complexes. Studies have shown that immunoprecipitation with SPC97 antibodies can co-precipitate Tub4p and Spc98p, confirming their presence in the same complexes .

• Western blotting: Following fractionation studies or immunoprecipitation, SPC97 antibodies can detect the protein in complex mixtures, enabling researchers to track its presence in different cellular fractions or experimental conditions.

When using epitope-tagged versions of SPC97 (e.g., SPC97-3HA), corresponding antibodies against the tag (e.g., anti-HA) can be employed in these techniques to circumvent issues related to native antibody production or specificity.

What are the recommended fixation methods for SPC97 immunofluorescence studies?

For optimal detection of SPC97 at the SPB by immunofluorescence, researchers should consider two fixation approaches depending on their experimental goals:

When studying SPB components including SPC97, methanol/acetone fixation has been shown to effectively preserve SPB antigens as described by Rout and Kilmartin (1990). This approach was successfully used to detect SPC97-3HA in combination with other SPB markers like Kar1p, confirming SPC97's localization to the SPB .

How can researchers distinguish between different SPC97-containing complexes?

Distinguishing between different SPC97-containing complexes requires combining multiple biochemical approaches:

• Sucrose gradient centrifugation: This technique separates protein complexes based on their sedimentation coefficients. Studies have identified a major 6S complex containing Tub4p, Spc98p, and Spc97p . Researchers can collect fractions from gradients ranging from 5-20% sucrose and analyze them by Western blotting with anti-SPC97 antibodies.

• Immunoprecipitation with different antibodies: Using antibodies against different components (anti-SPC97, anti-Tub4p, anti-Spc98p) can help determine which proteins are present in specific complexes. For example, researchers have shown that anti-SPC97-3HA antibodies co-precipitate both Spc98p and Tub4p, while control experiments show no precipitation in strains expressing untagged SPC97 .

• Two-hybrid analysis: This approach can determine direct protein-protein interactions. Studies have shown that SPC97 interacts with both Tub4p and Spc98p in the two-hybrid system, but not with itself . This suggests that SPC97 forms heteromeric rather than homomeric complexes.

The combination of these approaches has revealed that Tub4p, Spc98p, and Spc97p form trimeric complexes, with distinct domains of Spc98p mediating interactions with Tub4p and Spc97p respectively .

What experimental approaches can reveal the functional significance of SPC97 mutations?

To investigate the functional significance of SPC97 mutations, researchers should consider these experimental approaches:

• Generation of temperature-sensitive alleles: In vitro mutagenesis can create temperature-sensitive (ts) alleles of SPC97. For example, spc97-14 and spc97-20 have been used to study SPC97 function under restrictive conditions .

• Suppressor analysis: High-copy suppressor screens can identify genetic interactions. High-dosage expression of TUB4 or SPC98 suppresses some spc97(ts) alleles in an allele-specific manner, providing evidence for functional interactions . The table below illustrates how different spc97 alleles show distinct suppression patterns:

• Cytological analysis: Immunofluorescence microscopy with anti-tubulin antibodies can reveal spindle defects in mutant cells. Specific spc97 alleles show distinct phenotypes: spc97-14 cells exhibit defects in SPB separation or mitotic spindle formation, while spc97-20 cells show an additional defect in SPB duplication .

• Electron microscopy: Serial thin-section electron microscopy provides ultrastructural insights into SPB defects. Analysis of spc97-14 cells revealed duplicated SPBs either positioned side by side in the nuclear envelope or organizing abnormal spindles, while spc97-20 cells predominantly showed a single SPB, indicating severe defects in SPB duplication .

How can researchers assess the composition of SPC97-containing complexes across different experimental conditions?

To assess how SPC97-containing complex composition varies under different conditions, researchers should employ these approaches:

• Comparative immunoprecipitation: Immunoprecipitate SPC97 complexes from cells grown under different conditions (temperature shifts, cell cycle stages, drug treatments) and analyze co-precipitating proteins by Western blotting or mass spectrometry.

• Fractionation combined with quantitative analysis: Use sucrose gradient fractionation followed by quantitative Western blotting to determine the relative amounts of Tub4p, Spc98p, and SPC97 in complexes under different conditions. For example, researchers have identified a prominent 6S complex containing these proteins .

• In vivo cross-linking: Apply protein cross-linking prior to complex isolation to capture transient or unstable interactions that might be disrupted during standard immunoprecipitation procedures.

• Co-expression analysis: As demonstrated in studies of SPC97, co-overexpression experiments can reveal functional interactions. The toxicity of strong SPC97 overexpression is suppressed by co-overexpression of TUB4 or SPC98, indicating that these proteins interact and that their stoichiometry is critical for proper function .

This approach reveals whether complex composition or stoichiometry changes in response to experimental variables, providing insight into complex regulation and dynamics.

What controls are essential when using SPC97 antibodies for co-immunoprecipitation studies?

When performing co-immunoprecipitation with SPC97 antibodies, these controls are essential:

• Negative control with non-specific antibodies: Use isotype-matched control antibodies to ensure precipitations are specific to SPC97 recognition.

• Strain control: Include a strain expressing untagged SPC97 when using antibodies against epitope-tagged versions (e.g., SPC97-3HA). This control confirms specificity of immunoprecipitation for the tagged protein. Studies have shown no SPC97-3HA signal in precipitates from strains expressing untagged SPC97 .

• Reciprocal immunoprecipitation: Confirm interactions by performing reverse immunoprecipitations. For example, if anti-SPC97 antibodies co-precipitate Tub4p and Spc98p, then anti-Tub4p and anti-Spc98p antibodies should co-precipitate SPC97 .

• Irrelevant protein control: Include antibodies against proteins not expected to interact with SPC97. For instance, anti-Spc110p antibodies did not co-precipitate Tub4p, Spc98p, or SPC97-3HA, confirming the specificity of observed interactions .

• Input sample: Always analyze a portion of the input material alongside immunoprecipitated samples to confirm the presence of target proteins prior to immunoprecipitation.

These controls collectively ensure that observed co-immunoprecipitation results reflect genuine protein interactions rather than experimental artifacts.

What strategies can researchers use to validate SPC97 antibody specificity?

Validating SPC97 antibody specificity requires multiple complementary approaches:

• Western blot analysis of knockout/knockdown samples: Compare immunoreactivity in wild-type versus SPC97-deleted or depleted samples. Since SPC97 is essential in yeast, conditional mutants or degron-tagged versions must be used.

• Epitope competition assays: Pre-incubate antibodies with purified SPC97 protein or immunizing peptide before application to samples. Specific antibody binding should be blocked by this pre-incubation.

• Multiple antibodies targeting different epitopes: Use antibodies recognizing different regions of SPC97 and confirm consistent localization or immunoprecipitation results.

• Epitope-tagged protein comparison: Compare staining patterns between antibodies against native SPC97 and epitope-tagged versions (like SPC97-3HA). Consistent localization patterns support specificity .

• Cross-reactivity testing: Test antibodies on samples from different species or on other related proteins to assess potential cross-reactivity.

• Functional validation: Confirm that the antibody can disrupt SPC97 function when microinjected into cells or that it can deplete functional SPC97 from extracts.

Researchers studying SPC97 have employed epitope-tagged constructs (SPC97-3HA) extensively, which allows validation using both anti-HA and anti-SPC97 antibodies to confirm specificity of detected signals .

How can researchers optimize co-localization studies using SPC97 antibodies?

For optimal co-localization studies using SPC97 antibodies, implement these methodological approaches:

• Appropriate fixation method selection: As mentioned earlier, methanol/acetone fixation preserves SPB antigens better than formaldehyde fixation for immunofluorescence studies .

• Multi-color labeling controls: Include single-label controls to rule out bleed-through between fluorescence channels. This is particularly important when studying SPB components, which appear as small, intensely staining dots that can be difficult to distinguish.

• Sequential antibody application: When using multiple antibodies from the same species, apply them sequentially with an intermediate blocking step to prevent cross-reactivity.

• Super-resolution microscopy: Consider techniques like structured illumination microscopy (SIM) or stochastic optical reconstruction microscopy (STORM) to resolve closely positioned proteins at the SPB, which is below the resolution limit of conventional microscopy.

• Quantitative co-localization analysis: Use software tools that calculate Pearson's correlation coefficient or Manders' overlap coefficient to quantify the degree of co-localization between SPC97 and other proteins.

• Cell cycle synchronization: Synchronize cells to examine SPC97 localization at specific cell cycle stages, as SPB duplication and separation are cell cycle-dependent processes.

Studies have successfully employed these approaches to demonstrate that SPC97-3HA co-localizes with the SPB marker Kar1p in all cells examined (n>200) in non-synchronized cultures, confirming its consistent localization to the SPB throughout the cell cycle .

How should researchers interpret discrepancies between immunofluorescence and electron microscopy data for SPC97?

When faced with discrepancies between immunofluorescence and electron microscopy (EM) data for SPC97, consider these interpretation guidelines:

Careful integration of data from both techniques provides complementary information: immunofluorescence offers throughput and protein-specific detection, while EM provides detailed structural context.

What are the common pitfalls when analyzing SPC97 mutant phenotypes, and how can they be addressed?

When analyzing SPC97 mutant phenotypes, researchers should be aware of these potential pitfalls:

• Temperature effects: Temperature-sensitive mutants may show partial phenotypes at permissive temperatures or incomplete penetrance at restrictive temperatures. Ensure proper temperature control and include wild-type controls at all temperatures. Studies using spc97-14 and spc97-20 maintained strict temperature control during experiments .

• Secondary mutations: Suppressor mutations may arise during strain propagation. Regularly backcross strains and verify genotypes. The specificity of suppression by TUB4 and SPC98 provides strong evidence that the observed phenotypes are due to the spc97 mutations themselves .

• Pleiotropic effects: Primary defects may cause secondary consequences that complicate interpretation. Use time-course experiments and multiple assays to distinguish primary from secondary effects. For example, the study used both immunofluorescence and electron microscopy to characterize spindle defects in spc97 mutants .

• Quantification challenges: SPB and spindle phenotypes can be heterogeneous. Quantify phenotypes in large numbers of cells and classify them into distinct categories. The study quantified spindle morphologies in 100-200 cells for each strain and condition, as shown in this data table:

• Cell cycle effects: SPB duplication and spindle formation are cell-cycle regulated. Use cell synchronization to control for cell cycle position. The study synchronized cells with α-factor before releasing them at the restrictive temperature .

By addressing these pitfalls methodically, researchers can ensure robust phenotypic characterization of SPC97 mutants.

How can researchers resolve weak or inconsistent signals when using SPC97 antibodies?

To overcome weak or inconsistent signals when using SPC97 antibodies, implement these troubleshooting strategies:

• Antibody titration: Systematically test different antibody concentrations to determine the optimal working dilution. Too little antibody yields weak signals, while excess antibody can increase background.

• Epitope retrieval: If fixed samples show weak signals, try antigen retrieval methods like heat treatment or limited proteolysis to expose epitopes that might be masked during fixation.

• Signal amplification: For weak signals, consider using detection systems with signal amplification capabilities, such as tyramide signal amplification or polymer-based detection systems.

• Alternative fixation protocols: If standard fixation methods yield inconsistent results, test alternative protocols. The research showed that methanol/acetone fixation preserved SPB antigens better than other methods .

• Fresh antibody aliquots: Avoid repeated freeze-thaw cycles of antibodies by preparing single-use aliquots. Test new lots against previous ones to ensure consistent performance.

• Epitope-tagged constructs: If native protein detection is challenging, generate epitope-tagged versions like SPC97-3HA and use well-characterized commercial antibodies against the tag .

• Positive controls: Always include samples known to express SPC97 at detectable levels to confirm that weak signals result from technical issues rather than actual biological differences.

Studies of SPC97 have successfully employed epitope-tagged constructs and carefully optimized fixation methods to ensure consistent detection of this important SPB component .

How do SPC97-containing complexes compare structurally and functionally across different species?

Investigating SPC97-containing complexes across species presents an exciting frontier in cytoskeletal research:

• Comparative genomics and proteomics: While the yeast SPC97 protein shows no significant homology to other proteins in early database searches , subsequent research has identified potential homologs in other organisms. Advanced bioinformatic approaches can identify distant homologs based on structural predictions rather than sequence similarity alone.

• Reconstitution experiments: Purify SPC97-containing complexes from different species and compare their composition, stoichiometry, and activity in microtubule nucleation assays. In yeast, Tub4p, Spc98p and Spc97p form complexes with a sedimentation coefficient of ~6S . Determining whether similar complexes exist in other organisms would provide insight into evolutionary conservation.

• Cross-species complementation: Test whether SPC97 homologs from different species can rescue the phenotypes of yeast spc97 mutants. The allele-specific suppression of spc97 mutants by TUB4 and SPC98 provides a foundation for these experiments .

• Structural biology approaches: Apply cryo-electron microscopy or X-ray crystallography to determine the three-dimensional structures of SPC97-containing complexes from different species. Comparing these structures could reveal conserved interaction interfaces and species-specific adaptations.

• CRISPR-based genome editing: Generate equivalent mutations in SPC97 homologs across model organisms to determine whether they produce comparable phenotypes to those observed in yeast, such as defects in microtubule organizing center duplication or separation .

This comparative approach would significantly advance our understanding of microtubule organizing center evolution and function across eukaryotes.

What is the precise role of SPC97 in microtubule nucleation and organization?

The molecular mechanism by which SPC97 contributes to microtubule nucleation and organization remains incompletely understood and represents an important research direction:

• In vitro reconstitution: Purify recombinant SPC97, Tub4p (γ-tubulin), and Spc98p to reconstitute the complex in vitro and test its microtubule nucleation activity directly. Compare the activity of complete complexes versus subcomplexes or mutant versions.

• Structure-function analysis: Generate targeted mutations in different domains of SPC97 and assess their effects on complex formation, SPB localization, and microtubule organization. The study identified distinct phenotypes for different spc97 mutant alleles, suggesting domain-specific functions .

• Super-resolution microscopy: Apply techniques like expansion microscopy combined with single-molecule localization to precisely map the position of SPC97 relative to microtubule minus ends at the SPB in three dimensions.

• Live-cell imaging: Use fluorescently tagged SPC97 to track its dynamics during SPB duplication and spindle formation in living cells. Combine with photobleaching techniques to measure protein turnover at the SPB.

• Proximity labeling: Apply techniques like BioID or APEX2 proximity labeling with SPC97 as the bait to identify proteins that transiently interact with SPC97-containing complexes during microtubule nucleation.

• Cryo-electron tomography: Visualize the molecular architecture of the SPB with particular attention to how SPC97-containing complexes interact with microtubule minus ends at the inner and outer plaques, structures with which SPC97 is associated .

These approaches would provide mechanistic insight into how SPC97, together with its binding partners, contributes to the essential cellular processes of microtubule organization and spindle formation.

How might alterations in SPC97 interaction dynamics contribute to chromosomal instability in disease models?

While SPC97 research has primarily focused on yeast, investigating potential links between SPC97 homologs and disease presents compelling research opportunities:

• Cancer cell models: Analyze expression levels and mutation status of SPC97 homologs in cancer cell lines with chromosomal instability. Correlate alterations with spindle defects similar to those observed in spc97 mutant yeast (abnormal spindles, monopolar spindles) .

• CRISPR-based functional screening: Conduct genetic screens to identify synthetic lethal interactions with altered SPC97 homolog expression or function. This could reveal therapeutic vulnerabilities in cells with disrupted γ-tubulin complex function.

• Patient-derived xenografts: Examine SPC97 homolog expression, localization, and complex formation in patient-derived tumor samples grafted into model organisms. Correlate findings with tumor aggressiveness and response to anti-mitotic therapies.

• Inhibitor development and testing: Design small molecules targeting the interaction interfaces between SPC97 and its binding partners, based on the finding that these interactions are essential for proper spindle formation . Test their effects on normal and cancer cell division.

• Quantitative phosphoproteomics: Identify phosphorylation sites on SPC97 homologs that might regulate complex formation or activity during the cell cycle, potentially revealing new regulatory mechanisms that could be disrupted in disease.

• Interactome analysis across disease models: Compare the protein interaction networks of SPC97 homologs in normal cells versus disease models to identify altered interactions that might contribute to spindle defects and chromosomal instability.

This research direction could provide valuable insights into the contribution of centrosome and spindle abnormalities to cancer progression and potentially identify new therapeutic approaches.